Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand 别名地诺单抗 化学信息 分子量144.71 kDa CAS No.615258-40-7 密度no data available 储存&溶解度 存储store at low temperature | store at -20°C | Shipping with blue ice. ...
别名 AMG-162;IMMUNOGLOBULIN G2, ANTI-(HUMAN RANK LIGAND) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER;IMMUNOGLOBULIN G2, ANTI-(HUMAN OSTEOCLAST DIFFERENTIATION FACTOR) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AMG162 ...
Human Anti-Denosumab Antibody, clone AbD26296 是一个抗原决定簇特异的,专门识别单抗药物denosumab的抗独特型抗体。这个抗体不识别free RANKL (receptor activator of nuclear factor kappa-B ligand)或与人RANKL结合的denosumab。该抗体用于检测free denosumab及相似的产品,推荐在pharmacokinetic (PK) bridging ELISA中用于...
Denosumab is an anti-receptor activator of nuclear factor (NF)-kappaB (RANK) ligand human monoclonal antibody studied as a treatment for postmenopausal osteoporosis (PMO) and bone destruction due to rheumatoid arthritis (RA) or metastatic cancers. As of February 2009, the candidate was undergoing ...
RANKL(receptor activator of nuclear factor kappa B ligand,NF-κB受体活化因子配体)属于肿瘤坏死因子(tumour necrosis factor, TNF)配体超家族成员,在骨吸收的调控中发挥关键作用。通过特异性地结合RANKL,HLX14可阻断RANKL与破骨细胞表面的NF-κ...
Anti-hRANKL-hIgG2 is shipped at room temperature. Upon receipt, store at -20°C. Tags: buy Denosumab (anti-RANK ligand) | Denosumab (anti-RANK ligand) supplier | purchase Denosumab (anti-RANK ligand) | Denosumab (anti-RANK ligand) cost | Denosumab (anti-RANK ligand) manufacturer | or...
Prolia®is an antiresorptive RANK Ligand inhibitor, and its mechanism of action makes it different than a bisphosphonate.1-7 Mechanism of action differences are not meant to imply clinical efficacy. As an essential mediator of osteoclast activity, increased RANK Ligand may lead to increased bone ...
Denosumab (anti-receptor activator of nuclear factorκB ligand [RANKL] antibody) is a novel agent, a fully human monoclonal antibody that inhibits osteoclastic-medicated bone resorption by binding to osteoblast-produced RANKL. By reducing RANKL binding to the osteoclast receptor RANK, bone resorption ...
Denosumabis a human anti-RANK ligand (RANKL) monoclonal antibody that has been developed to inhibit osteoclasts. In addition to its applications in osteoporosis and cancer, denosumab may protect against joint destruction in RA. RANKL is a key mediator of osteoclast formation, function, and survival...
RANK Ligand Description Denosumab, which was approved in the United States in 2010, is a fully human sequence IgG2 monoclonal antibody that inhibits bone resorption by blocking the activity of receptor activator of nuclear factor-κB ligand (RANKL). RANKL is a TNF family protein that is expressed...